目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 KEY STAKEHOLDERS

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA SOURCES
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION METHODOLOGY
2.3 RECESSION IMPACT ASSESSMENT APPROACH
2.4 MARKET DATA VALIDATION AND TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW
5.1 MARKET DYNAMICS
5.1.1 DRIVERS
5.1.2 RESTRAINTS
5.1.3 OPPORTUNITIES
5.1.4 CHALLENGES
5.2 REGULATORY LANDSCAPE BY REGION (AS OF 2023)
5.2.1 NORTH AMERICA
5.2.2 EUROPE
5.2.3 ASIA-PACIFIC
5.2.4 LATIN AMERICA
5.2.5 MIDDLE EAST AND AFRICA
5.3 PRODUCT SEGMENTS - AVERAGE SELLING PRICE TRENDS BY REGION (AS OF 2022)
5.3.1 NORTH AMERICA
5.3.2 EUROPE
5.3.3 ASIA-PACIFIC
5.3.4 LATIN AMERICA
5.3.5 MIDDLE EAST AND AFRICA
5.4 VALUE CHAIN ANALYSIS
5.5 ECOSYSTEM LANDSCAPE
5.6 REIMBURSEMENT SCENARIO
5.7 PORTER'S FIVE FORCES ANALYSIS
5.8 PATENT ANALYSIS
5.9 SUPPLY CHAIN ANALYSIS
5.10 TRADE ANALYSIS
5.11 TECHNOLOGICAL ANALYSIS
5.12 KEY CONFERENCES & EVENTS IN 2022-2024
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA

6 DEFIBRILLATORS MARKET VALUE DATA, BY PRODUCT (USD MILLION; 2021-2028)*
6.1 INTRODUCTION
6.2 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS
6.2.1 TRANSVENOUS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS
6.2.1.1 BIVENTRICULAR ICDS/CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATORS
6..2.1.2 DUAL-CHAMBER ICDS
6.2.1.3 SINGLE-CHAMBER ICDS
6.2.2 SUBCUTANEOUS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS
6.3 EXTERNAL DEFIBRILLATORS
6.3.1 SEMI-AUTOMATED EXTERNAL DEFIBRILLATORS
6.3.2 FULLY AUTOMATED EXTERNAL DEFIBRILLATORS
6.3.3 WEARABLE CARDIOVERTER DEFIBRILLATORS

7 DEFIBRILLATORS MARKET VALUE DATA, BY PATIENT TYPE (USD MILLION; USD MILLION; 2021-2028)*
7.1 INTRODUCTION
7.2 ADULT PATIENT
7.3 PEDIATRIC PATIENT

8 DEFIBRILLATORS MARKET VALUE DATA, BY END USER (USD MILLION; 2021-2028)*
8.1 INTRODUCTION
8.2 HOSPITALS, CLINICS, CARDIAC CENTERS
8.3 PRE-HOSPITAL CARE SETTINGS
8.4 PUBLIC ACCESS MARKETS
8.5 HOME CARE SETTINGS
8.6 ALTERNATE CARE FACILITIES
8.7 OTHER END USER

9 DEFIBRILLATORS MARKET VALUE DATA, BY REGION (USD MILLION; 2021-2028)
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA
9.3 EUROPE
9.3.1 GERMANY
9.3.2 FRANCE
9.3.3 UK
9.3.4 SPAIN
9.3.5 ITALY
9.3.6 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 JAPAN
9.4.2 CHINA
9.4.3 INDIA
9.4.4 AUSTRALIA
9.4.5 SOUTH KOREA
9.4.6 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 BRAZIL
9.5.2 MEXICO
9.5.3 REST OF LATIN AMERICA
9.6 MIDDLE EAST AND AFRICA

10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 GLOBAL DEFIBRILLATORS MARKET SHARE ANALYSIS OF TOP 5 KEY PLAYERS (IN TERMS OF REVENUE SHARE % AS OF 2022)
10.3 COMPETITIVE SITUATION AND TRENDS (2021-2023)
10.4 VENDOR MAPPING ANALYSIS FOR TOP 25 GLOBAL PLAYERS (AS OF 2023)
10.4.1 VISIONARY LEADERS
10.4.2 INNOVATORS
10.4.3 DYNAMIC DIFFERENTIATORS
10.4.4 EMERGING COMPANIES

11 COMPANY PROFILES**
(Overview, Products Offered, Recent Developments during 2021-2023) ***
11.1 MEDTRONIC
11.2 STRYKER.
11.3 KONINKLIJKE PHILIPS N.V.
11.4 ASAHI KASEI CORPORATION
11.5 BOSTON SCIENTIFIC CORPORATION
11.6 ABBOTT
11.7 MICROPORT SCIENTIFIC CORPORATION
11.8 NIHON KOHDEN CORPORATION
11.9 BIOTRONIK.
11.10 CU MEDICAL SYSTEMS, INC.
11.11 METSIS MEDIKAL
11.12 MEDIANA CO.,LTD
11.13 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD..
11.14 PROGETTI SRL .
11.15 SCHILLER AG
11.16 BPL MEDICAL TECHNOLOGIES
11.17 METRAX GMBH
11.18 AMI ITALIA
11.19 AVIVE SOLUTIONS, INC.
11.20 BEXEN CARDIO.

12 APPENDIX